{"id":40710,"date":"2025-09-04T15:47:58","date_gmt":"2025-09-04T07:47:58","guid":{"rendered":"https:\/\/flcube.com\/?p=40710"},"modified":"2025-09-04T15:47:59","modified_gmt":"2025-09-04T07:47:59","slug":"boji-medicals-fczr-approved-for-otomycosis-trials-first-liquid-eardrop-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=40710","title":{"rendered":"Boji Medical\u2019s FCZR Approved for Otomycosis Trials \u2013 First Liquid Eardrop in China"},"content":{"rendered":"\n<p><strong>Boji Medical Technology Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/300404:SHE\">SHE: 300404<\/a>) has secured approval from the <strong>National Medical Products Administration (NMPA)<\/strong> to initiate clinical trials of <strong>FCZR<\/strong>, a Class\u202f2.2\/2.4 improved new drug designed specifically for the treatment of <strong>otomycosis<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-why-fczr-matters\">Why FCZR Matters<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Optimized Formulation<\/strong> \u2013 FCZR is a liquid eardrop that delivers the active ingredient directly to the ear canal, ensuring full contact with lesions even in hidden corners.<\/li>\n\n\n\n<li><strong>Localised Action<\/strong> \u2013 By concentrating the drug at the site of infection, FCZR promises a faster, more complete cure while reducing systemic exposure.<\/li>\n\n\n\n<li><strong>First\u2011Mover Advantage<\/strong> \u2013 No other liquid eardrop with this clinical profile is approved for marketing in China or internationally, positioning FCZR as a unique solution in the ENT market.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-disease-landscape\">Disease Landscape<\/h2>\n\n\n\n<p>Otomycosis, a fungal infection of the external ear canal, is common in hot, humid climates and often recurs. Conventional treatments rely on multi\u2011step regimens that can be inconvenient and less effective. FCZR\u2019s single\u2011dose, user\u2011friendly format addresses these shortcomings and could redefine standard care.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-next-steps\">Next Steps<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Phase\u202fI\/II Trials<\/strong> \u2013 The NMPA\u2011approved study will enroll patients across multiple ENT centers in China, evaluating safety, tolerability, and preliminary efficacy.<\/li>\n\n\n\n<li><strong>Regulatory Pathway<\/strong> \u2013 Successful trial outcomes will pave the way for a marketing application under the Class\u202f2.2\/2.4 pathway, potentially granting Boji a first\u2011to\u2011market position.<\/li>\n\n\n\n<li><strong>Global Expansion<\/strong> \u2013 Boji plans to explore approvals outside China, leveraging its experience with Class\u202f2.4 products and a growing international regulatory portfolio.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-investment-implications\">Investment Implications<\/h2>\n\n\n\n<p>Boji\u2019s successful navigation of the NMPA approval process showcases its capability to develop and advance innovative ENT therapies. The FCZR pipeline, coupled with the company\u2019s CRO expertise, positions Boji as a compelling candidate for investors interested in niche therapeutic areas with high unmet need.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/\u535a\u6d4e\u533b\u836f\uff1a\u5173\u4e8e\u516c\u53f8\u83b7\u5f97\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u535a\u6d4e\u533b\u836f\uff1a\u5173\u4e8e\u516c\u53f8\u83b7\u5f97\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-70063a87-ee59-4419-a46d-722a8635fd70\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/\u535a\u6d4e\u533b\u836f\uff1a\u5173\u4e8e\u516c\u53f8\u83b7\u5f97\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a.pdf\">\u535a\u6d4e\u533b\u836f\uff1a\u5173\u4e8e\u516c\u53f8\u83b7\u5f97\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/\u535a\u6d4e\u533b\u836f\uff1a\u5173\u4e8e\u516c\u53f8\u83b7\u5f97\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-70063a87-ee59-4419-a46d-722a8635fd70\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Boji Medical Technology Co., Ltd. (SHE: 300404) has secured approval from the National Medical Products&#8230;<\/p>\n","protected":false},"author":1,"featured_media":40712,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[2956,62,1170],"class_list":["post-40710","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-boji-medical-technology","tag-clinical-trial-approval-initiation","tag-she-300404"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Boji Medical\u2019s FCZR Approved for Otomycosis Trials \u2013 First Liquid Eardrop in China - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China\u2011based CRO Boji Medical Technology (SHE:\u202f300404) announces NMPA approval to launch clinical trials of **FCZR**, a novel Class\u202f2.2\/2.4 liquid eardrop that targets otomycosis with a localized delivery advantage. No similar product is currently marketed in China or abroad.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=40710\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Boji Medical\u2019s FCZR Approved for Otomycosis Trials \u2013 First Liquid Eardrop in China\" \/>\n<meta property=\"og:description\" content=\"China\u2011based CRO Boji Medical Technology (SHE:\u202f300404) announces NMPA approval to launch clinical trials of **FCZR**, a novel Class\u202f2.2\/2.4 liquid eardrop that targets otomycosis with a localized delivery advantage. No similar product is currently marketed in China or abroad.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=40710\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-04T07:47:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-04T07:47:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0413.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40710#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40710\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Boji Medical\u2019s FCZR Approved for Otomycosis Trials \u2013 First Liquid Eardrop in China\",\"datePublished\":\"2025-09-04T07:47:58+00:00\",\"dateModified\":\"2025-09-04T07:47:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40710\"},\"wordCount\":300,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40710#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0413.webp\",\"keywords\":[\"Boji Medical Technology\",\"Clinical trial approval \\\/ initiation\",\"SHE: 300404\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40710#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40710\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=40710\",\"name\":\"Boji Medical\u2019s FCZR Approved for Otomycosis Trials \u2013 First Liquid Eardrop in China - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40710#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40710#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0413.webp\",\"datePublished\":\"2025-09-04T07:47:58+00:00\",\"dateModified\":\"2025-09-04T07:47:59+00:00\",\"description\":\"China\u2011based CRO Boji Medical Technology (SHE:\u202f300404) announces NMPA approval to launch clinical trials of **FCZR**, a novel Class\u202f2.2\\\/2.4 liquid eardrop that targets otomycosis with a localized delivery advantage. No similar product is currently marketed in China or abroad.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40710#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40710\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40710#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0413.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0413.webp\",\"width\":1080,\"height\":608,\"caption\":\"Boji Medical\u2019s FCZR Approved for Otomycosis Trials \u2013 First Liquid Eardrop in China\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40710#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Boji Medical\u2019s FCZR Approved for Otomycosis Trials \u2013 First Liquid Eardrop in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Boji Medical\u2019s FCZR Approved for Otomycosis Trials \u2013 First Liquid Eardrop in China - Insight, China&#039;s Pharmaceutical Industry","description":"China\u2011based CRO Boji Medical Technology (SHE:\u202f300404) announces NMPA approval to launch clinical trials of **FCZR**, a novel Class\u202f2.2\/2.4 liquid eardrop that targets otomycosis with a localized delivery advantage. No similar product is currently marketed in China or abroad.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=40710","og_locale":"en_US","og_type":"article","og_title":"Boji Medical\u2019s FCZR Approved for Otomycosis Trials \u2013 First Liquid Eardrop in China","og_description":"China\u2011based CRO Boji Medical Technology (SHE:\u202f300404) announces NMPA approval to launch clinical trials of **FCZR**, a novel Class\u202f2.2\/2.4 liquid eardrop that targets otomycosis with a localized delivery advantage. No similar product is currently marketed in China or abroad.","og_url":"https:\/\/flcube.com\/?p=40710","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-04T07:47:58+00:00","article_modified_time":"2025-09-04T07:47:59+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0413.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=40710#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=40710"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Boji Medical\u2019s FCZR Approved for Otomycosis Trials \u2013 First Liquid Eardrop in China","datePublished":"2025-09-04T07:47:58+00:00","dateModified":"2025-09-04T07:47:59+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=40710"},"wordCount":300,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=40710#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0413.webp","keywords":["Boji Medical Technology","Clinical trial approval \/ initiation","SHE: 300404"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=40710#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=40710","url":"https:\/\/flcube.com\/?p=40710","name":"Boji Medical\u2019s FCZR Approved for Otomycosis Trials \u2013 First Liquid Eardrop in China - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=40710#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=40710#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0413.webp","datePublished":"2025-09-04T07:47:58+00:00","dateModified":"2025-09-04T07:47:59+00:00","description":"China\u2011based CRO Boji Medical Technology (SHE:\u202f300404) announces NMPA approval to launch clinical trials of **FCZR**, a novel Class\u202f2.2\/2.4 liquid eardrop that targets otomycosis with a localized delivery advantage. No similar product is currently marketed in China or abroad.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=40710#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=40710"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=40710#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0413.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0413.webp","width":1080,"height":608,"caption":"Boji Medical\u2019s FCZR Approved for Otomycosis Trials \u2013 First Liquid Eardrop in China"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=40710#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Boji Medical\u2019s FCZR Approved for Otomycosis Trials \u2013 First Liquid Eardrop in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0413.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40710","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=40710"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40710\/revisions"}],"predecessor-version":[{"id":40713,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40710\/revisions\/40713"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/40712"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=40710"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=40710"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=40710"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}